- Home
- LU vs ANIP Comparison
LU vs ANIP Comparison
Compare LU & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LU | ANIP |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LU | ANIP |
|---|---|---|
| Price | $2.54 | $84.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $99.29 |
| AVG Volume (30 Days) | ★ 1.6M | 450.7K |
| Earning Date | 03-23-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.67 |
| Revenue | ★ $4,671,260,668.00 | $826,880,000.00 |
| Revenue This Year | N/A | $40.23 |
| Revenue Next Year | N/A | $9.65 |
| P/E Ratio | ★ N/A | $50.43 |
| Revenue Growth | N/A | ★ 48.87 |
| 52 Week Low | $2.25 | $52.50 |
| 52 Week High | $4.57 | $99.50 |
Technical Indicators
Market Signals| Indicator | LU | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 38.01 | 44.13 |
| Support Level | $2.37 | $77.99 |
| Resistance Level | $2.63 | $85.24 |
| Average True Range (ATR) | 0.10 | 2.73 |
| MACD | 0.02 | 0.25 |
| Stochastic Oscillator | 31.85 | 50.37 |
Price Performance
Historical ComparisonAbout LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.